Voyageur Pharmaceuticals Ltd

As of May 31, 2026, Voyageur Pharmaceuticals Ltd carries a market capitalization of 17.05M, placing it among publicly traded companies globally. Its enterprise value stands at 16.65M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Voyageur Pharmaceuticals Ltd's next confirmed earnings release is scheduled for November 2, 2026.

As of May 31, 2026, Voyageur Pharmaceuticals Ltd has 179.48M shares outstanding.

These figures are as of May 31, 2026.

As of May 31, 2026, Voyageur Pharmaceuticals Ltd maintains a current ratio of 0.23, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.

As of the close on August 26, 2026, Voyageur Pharmaceuticals Ltd's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.15, while the 200-day moving average is 0.13.

As of May 31, 2026, Voyageur Pharmaceuticals Ltd holds 441,874.00 in cash and equivalents against 40,000.00 in total debt, resulting in a net debt position of -401,874.00. Total book value stands at 408,205.00, with working capital of -2.17M providing operational flexibility.

Voyageur Pharmaceuticals Ltd produced -1.30M in operating cash flow over the twelve months ended May 31, 2026.

These figures cover the twelve months ended May 31, 2026. Free cash flow yield is negative at -7.75: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.57, meaning Voyageur Pharmaceuticals Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Voyageur Pharmaceuticals Ltd's most recent stock split took place on March 7, 2017 with a 2:1 split ratio.